Aktie A3EQ6J CLEO DIAGNOSTICS LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Cleo Diagnostics Ltd

Aktien

A3EQ6J

AU0000288045

COV

Verzögert Australian S.E.
Andere Börsenplätze
 05:09:58 27.06.2024 		% 5 Tage % 1. Jan.
0.31 AUD +3.33% Intraday Chart für Cleo Diagnostics Ltd -4.62% +77.14%
29.05. Studie findet Cleo Diagnostics ' Bluttest ubertrifft klinische Benchmarks MT
02.04. CLEO zapft HcFocus für US Markteintritt an MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Cleo Diagnostics Secures US FDA Feedback for Ovarian Cancer Test
7,500,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 23-JUN-2024.
Study Finds Cleo Diagnostics ' Blood Test Outperforms Clinical Benchmarks
Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials
CLEO Taps HcFocus for US Market Entry
Cleo Diagnostics Concludes Design Transfer of Ovarian Cancer Detection Test Technology
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 1-DEC-2023.
162,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-NOV-2023.
Cleo Diagnostics Confirms Efficacy of Ovarian Cancer Test from Validation Study; Shares Surge 21%
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 4-NOV-2023.
425,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-OCT-2023.
75,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-OCT-2023.
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 18-OCT-2023.
100,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 13-OCT-2023.
Cleo Diagnostics Advances Development of Cancer Test Kit
CLEO Diagnostics’ Chief Scientific Officer Move to Full-Time Arrangement
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-SEP-2023.
125,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-SEP-2023.
37,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-SEP-2023.
CLEO Diagnostics Secures US Patent for Ovarian Cancer Biomarker Testing
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3EQ6J Aktie
  4. Nachrichten Cleo Diagnostics Ltd
  5. Andere Sprachen